Sofinnova Partners SAS 4
4 · CinCor Pharma, Inc. · Filed Jan 13, 2022
Insider Transaction Report
Form 4
Sofinnova Partners SAS
10% Owner
Transactions
- Conversion
Common Stock
2022-01-11+3,867,646→ 3,867,646 total(indirect: By Sofinnova Capital IX) - Purchase
Common Stock
2022-01-11$16.00/sh+220,000$3,520,000→ 4,087,646 total(indirect: By Sofinnova Capital IX) - Conversion
Series A Preferred Stock
2022-01-11−9,999,999→ 0 total(indirect: By Sofinnova Capital IX)→ Common Stock (2,941,176 underlying) - Conversion
Series B Preferred Stock
2022-01-11−3,150,000→ 0 total(indirect: By Sofinnova Capital IX)→ Common Stock (926,470 underlying)
Footnotes (2)
- [F1]Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a 3.4:1 basis, and had no expiration date.
- [F2]The shares are directly held by Sofinnova Capital IX ("SC IX"). Sofinnova Partners SAS ("Sofinnova Partners") is the management company of SC IX and may be deemed to share voting and investment power over the shares held by SC IX. Sofinnova Partners disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein.